Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24495599 | 0.74 | ADORA2A (0.39) | MEN1KMT2ATGFBR1TGFBR2P2RX3 | |
| SCHEMBL24095615 | 0.73 | ALDH1A1 (0.39) | MEN1KMT2ATGFBR1P2RX3 | |
| SCHEMBL19505265 | 0.71 | P2RX3 (0.35) | MEN1KMT2AP2RX3 | |
| SCHEMBL25996795 | 0.68 | P2RX3 (0.39) | P2RX3 | |
| SCHEMBL19375462 | 0.66 | P2RX3 (0.46) | P2RX3 | |
| SCHEMBL20786627 | 0.65 | DGAT1 (0.30) | — | |
| SCHEMBL20787899 | 0.65 | TRPA1 (0.35) | P2RX3 | |
| SCHEMBL22105454 | 0.65 | ADORA2A (0.38) | TGFBR1TGFBR2P2RX3 | |
| SCHEMBL20432337 | 0.65 | P2RX3 (0.46) | P2RX3 | |
| SCHEMBL21527477 | 0.64 | ALDH1A1 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | MEN1 3286/4885KMT2A 4474/4885TGFBR1 1755/4885 |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | TRPC5, TRPM5, TRPC4 | MEN1 4208/4885KMT2A 4085/4885TGFBR1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.